Biocept, Inc.
5810 Nancy Ridge Drive
San Diego, CA 92121
May 18, 2023
VIA EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Attn: Jessica Ansart
| Re: | Biocept, Inc. |
Registration Statement on Form S-1, as amended (File No. 333-271355)
Ladies and Gentlemen:
Biocept, Inc. (the “Company”) hereby withdraws its request, dated May 16, 2023, that the effective date of the above-referenced Registration Statement on Form S-1 (the “Registration Statement”) be accelerated to 9:00 a.m., Eastern Time, on May 18, 2023. The Company intends to submit a revised acceleration request for the Registration Statement at a later date.
Please contact Charles J. Bair of Cooley LLP at (858) 550-6142 or Asa M. Henin of Cooley LLP at (858) 550-6104, counsel to the Company, if there are any questions regarding this matter.
| Very truly yours, |
| Biocept, Inc. |
| /s/ Samuel D. Riccitelli |
| By: Samuel D. Riccitelli |
| Title: Interim President and Chief Executive Officer |